Jamieson, David <br/><br/>
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.  [electronic resource] 

 -  European journal of cancer (Oxford, England : 1990)  11 2016 
 - 1-10 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-0852 
<br/><br/><label>Standard No.: </label>10.1016/j.ejca.2016.08.026  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abdominal Pain--chemically induced<br/>Administration, Oral<br/>Adult<br/>Aged<br/>Allosteric Regulation<br/>Anorexia--chemically induced<br/>Bile Duct Neoplasms--drug therapy<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cholangiocarcinoma--drug therapy<br/>Chromatography, High Pressure Liquid<br/>Chromatography, Liquid<br/>Colorectal Neoplasms--drug therapy<br/>Diarrhea--chemically induced<br/>Drug Eruptions--etiology<br/>Esophageal Neoplasms--drug therapy<br/>Fatigue--chemically induced<br/>Female<br/>Glycogen Synthase Kinase 3 beta--drug effects<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>MAP Kinase Kinase 1--antagonists & inhibitors<br/>MAP Kinase Kinase 2--antagonists & inhibitors<br/>Male<br/>Maximum Tolerated Dose<br/>Mesothelioma--drug therapy<br/>Middle Aged<br/>Mitogen-Activated Protein Kinase 1--drug effects<br/>Mitogen-Activated Protein Kinase 3--drug effects<br/>Nausea--chemically induced<br/>Neoplasms--drug therapy<br/>Pancreatic Neoplasms--drug therapy<br/>Phosphoproteins--drug effects<br/>Protein Kinase Inhibitors--adverse effects<br/>Proto-Oncogene Proteins c-akt--drug effects<br/>Ribosomal Protein S6 Kinases, 70-kDa--drug effects<br/>Tandem Mass Spectrometry<br/>Uterine Cervical Neoplasms--drug therapy